Selected Publications

  1. Jin, N.; Babiloni, C.; Drinkenburg, W. H.; Hajós, M.; Nygaard, H. B.; Tanila, H. Recommendations for preclinical testing of treatments against Alzheimer’s disease-related epileptiform spikes in transgenic rodent models. Journal of Alzheimer's Disease 2022, 88 (3), 849-865.

  2. Montero-Odasso, M.; Zou, G. Y.; Kamkar, N.; Feldman, H. H.; Belleville, S.; Chertkow, H.; Nygaard, H. B.; Son, S.; Speechley, M. Multidomain trials to prevent dementia: addressing methodological challenges. Alzheimer's Research & Therapy 2022, 14 (1), 1-5.

  3. Wendt, S.; Johnson, S.; Weilinger, N. L.; Groten, C.; Sorrentino, S.; Frew, J.; Yang, L.; Choi, H. B.; Nygaard, H. B.; MacVicar, B. A. Simultaneous imaging of redox states in dystrophic neurites and microglia at Aβ plaques indicate lysosome accumulation not microglia correlate with increased oxidative stress. Redox Biology 2022, 56, 102448.

  4. Chaudhury, H.; Mahal, T.; Seetharaman, K.; Nygaard, H. B. Community participation in activities and places among older adults with and without dementia. Dementia 2021, 20 (4), 1213-1233.

  5. Frew, J.; Nygaard, H. B. Neuropathological and behavioral characterization of aged Grn R493X progranulin-deficient frontotemporal dementia knockin mice. Acta Neuropathologica Communications 2021, 9 (1), 1-16.

  6. Kent, B. A.; Feldman, H. H.; Nygaard, H. B. Sleep and its regulation: An emerging pathogenic and treatment frontier in Alzheimer’s disease. Progress in neurobiology 2021, 197, 101902.

  7. Frew, J.; Baradaran-Heravi, A.; Balgi, A. D.; Wu, X.; Yan, T. D.; Arns, S.; Shidmoossavee, F. S.; Tan, J.; Jaquith, J. B.; Jansen-West, K. R.; et al. Premature termination codon readthrough upregulates progranulin expression and improves lysosomal function in preclinical models of GRN deficiency. Mol Neurodegener 2020, 15 (1), 21. DOI: 10.1186/s13024-020-00369-5  From NLM.

  8. Lee, C.; Willerth, S. M.; Nygaard, H. B. The Use of Patient-Derived Induced Pluripotent Stem Cells for Alzheimer's Disease Modeling. Prog Neurobiol 2020, 192, 101804. DOI: 10.1016/j.pneurobio.2020.101804  From NLM.

  9. Frew, J.; Wu, X.; Hsiung, G. Y.; Feldman, H. H.; Mackenzie, I. R.; Nygaard, H. B. Generation of an induced pluripotent stem cell line (UBCi001-a) from a presymptomatic individual carrying the R418X progranulin gene mutation. Stem Cell Research 2019, 41, 101582.

  10. Kent, B. A.; Michalik, M.; Marchant, E. G.; Yau, K. W.; Feldman, H. H.; Mistlberger, R. E.; Nygaard, H. B. Delayed daily activity and reduced NREM slow-wave power in the APPswe/PS1dE9 mouse model of Alzheimer's disease. Neurobiology of Aging 2019, 78, 74-86.

  11. Nygaard, H. B.; Erson-Omay, E. Z.; Wu, X.; Kent, B. A.; Bernales, C. Q.; Evans, D. M.; Farrer, M. J.; Vilariño-Güell, C.; Strittmatter, S. M. Whole-exome sequencing of an exceptional longevity cohort. The Journals of Gerontology: Series A 2019, 74 (9), 1386-1390.

  12. Van Dyck, C. H.; Nygaard, H. B.; Chen, K.; Donohue, M. C.; Raman, R.; Rissman, R. A.; Brewer, J. B.; Koeppe, R. A.; Chow, T. W.; Rafii, M. S. Effect of AZD0530 on cerebral metabolic decline in Alzheimer disease: a randomized clinical trial. JAMA neurology 2019, 76 (10), 1219-1229.

  13. Kent, B. A.; Strittmatter, S. M.; Nygaard, H. B. Sleep and EEG power spectral analysis in three transgenic mouse models of Alzheimer’s disease: APP/PS1, 3xTgAD, and Tg2576. Journal of Alzheimer's Disease 2018, 64 (4), 1325-1336.

  14. Nygaard, H. B. Targeting Fyn Kinase in Alzheimer's Disease. Biol Psychiatry 2018, 83 (4), 369-376. DOI: 10.1016/j.biopsych.2017.06.004  From NLM.

  15. Lichtenstein, M. L.; Dwosh, E.; Chowdhury, A. R.; Farrer, M. J.; McKenzie, M. B.; Guella, I.; Evans, D. M.; Nygaard, H. B.; Shewchuk, J. R.; Hayden, S. Neurobehavioral characterization of adult-onset Alexander disease: A family study. Neurology: Clinical Practice 2017, 7 (5), 425-429.

  16. Vossel, K. A.; Tartaglia, M. C.; Nygaard, H. B.; Zeman, A. Z.; Miller, B. L. Epileptic activity in Alzheimer's disease: causes and clinical relevance. The Lancet Neurology 2017, 16 (4), 311-322.

  17. Kaufman, A. C.; Salazar, S. V.; Haas, L. T.; Yang, J.; Kostylev, M. A.; Jeng, A. T.; Robinson, S. A.; Gunther, E. C.; van Dyck, C. H.; Nygaard, H. B. Fyn inhibition rescues established memory and synapse loss in A lzheimer mice. Annals of neurology 2015, 77 (6), 953-971.

  18. Kostylev, M. A.; Kaufman, A. C.; Nygaard, H. B.; Patel, P.; Haas, L. T.; Gunther, E. C.; Vortmeyer, A.; Strittmatter, S. M. Prion-protein-interacting amyloid-β oligomers of high molecular weight are tightly correlated with memory impairment in multiple Alzheimer mouse models. Journal of Biological Chemistry 2015, 290 (28), 17415-17438.

  19. Nygaard, H. B.; Kaufman, A. C.; Sekine-Konno, T.; Huh, L. L.; Going, H.; Feldman, S. J.; Kostylev, M. A.; Strittmatter, S. M. Brivaracetam, but not ethosuximide, reverses memory impairments in an Alzheimer’s disease mouse model. Alzheimer's Research & Therapy 2015, 7 (1), 1-12.

  20. Nygaard, H. B.; Wagner, A. F.; Bowen, G. S.; Good, S. P.; MacAvoy, M. G.; Strittmatter, K. A.; Kaufman, A. C.; Rosenberg, B. J.; Sekine-Konno, T.; Varma, P. A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease. Alzheimer's research & therapy 2015, 7 (1), 1-11.

  21. Nygaard, H. B.; Lippa, C. F.; Mehdi, D.; Baehring, J. M. A novel presenilin 1 mutation in early-onset Alzheimer’s disease with prominent frontal features. American Journal of Alzheimer's Disease & Other Dementias® 2014, 29 (5), 433-435.

  22. Nygaard, H. B.; van Dyck, C. H.; Strittmatter, S. M. Fyn kinase inhibition as a novel therapy for Alzheimer’s disease. Alzheimer's research & therapy 2014, 6, 1-8.

  23. Couch, B. A.; Kerrisk, M. E.; Kaufman, A. C.; Nygaard, H. B.; Strittmatter, S. M.; Koleske, A. J. Delayed amyloid plaque deposition and behavioral deficits in outcrossed AβPP/PS1 mice. Journal of Comparative Neurology 2013, 521 (6), 1395-1408.

  24. Nygaard, H. B. Current and emerging therapies for Alzheimer’s disease. Clinical therapeutics 2013, 35 (10), 1480-1489.

  25. Um, J. W.; Nygaard, H. B.; Heiss, J. K.; Kostylev, M. A.; Stagi, M.; Vortmeyer, A.; Wisniewski, T.; Gunther, E. C.; Strittmatter, S. M. Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nature neuroscience 2012, 15 (9), 1227-1235.

  26. Gimbel, D. A.; Nygaard, H. B.; Coffey, E. E.; Gunther, E. C.; Laurén, J.; Gimbel, Z. A.; Strittmatter, S. M. Memory impairment in transgenic Alzheimer mice requires cellular prion protein. Journal of Neuroscience 2010, 30 (18), 6367-6374.

  27. Zhang, Y.; Kurup, P.; Xu, J.; Carty, N.; Fernandez, S. M.; Nygaard, H. B.; Pittenger, C.; Greengard, P.; Strittmatter, S. M.; Nairn, A. C. Genetic reduction of striatal-enriched tyrosine phosphatase (STEP) reverses cognitive and cellular deficits in an Alzheimer’s disease mouse model. Proceedings of the National Academy of Sciences 2010, 107 (44), 19014-19019.

  28. Laurén, J.; Gimbel, D. A.; Nygaard, H. B.; Gilbert, J. W.; Strittmatter, S. M. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers. Nature 2009, 457 (7233), 1128-1132.

  29. Linhoff, M. W.; Laurén, J.; Cassidy, R. M.; Dobie, F. A.; Takahashi, H.; Nygaard, H. B.; Airaksinen, M. S.; Strittmatter, S. M.; Craig, A. M. An unbiased expression screen for synaptogenic proteins identifies the LRRTM protein family as synaptic organizers. Neuron 2009, 61 (5), 734-749.

  30. Nygaard, H. B.; Shenoi, S.; Shukla, S. Lower back pain caused by tophaceous gout of the spine. Neurology 2009, 73 (5), 404-404.

  31. Nygaard, H. B.; Strittmatter, S. M. Cellular prion protein mediates the toxicity of β-amyloid oligomers: implications for Alzheimer disease. Archives of neurology 2009, 66 (11), 1325-1328.